Pay in 4 interest-free payments of $6.41 Learn more
Ships within 48 hours · Estimated delivery Sep 5 - Sep 10
In a randomized, single-blind, 24-week study, participants assigned to dual therapy of 2 mg weekly of the GLP-1 receptor agonist exenatide (Bydureon, AstraZeneca) and 10 mg daily of the SGLT2 inhibitor dapagliflozin (Farxiga, AstraZeneca) lost more weight than those taking either agent alone or those receiving dapagliflozin and metformin extended-release (Xigduo XL, AstraZeneca) or phentermine/topiramate extended-release (Qsymia, Vivus)
Primary sites (ranked by absorption speed): Rotation pattern
Unlike medications or surgeries, peptide therapy is a non-invasive, targeted treatment that works with the bodys natural processes to improve overall health
The researchers noted that even without weight loss, GLP-1 drugs and MHRMs may help lower blood pressure
US$ 28.96
US$ 21.83
US$ 22.12
